Abstract Details

Title Determinants of Recovery from the Coronavirus Disease 2019 in People with Multiple Sclerosis: The UK MS Register COVID-19 Prospective Cohort Study

Topic Multiple Sclerosis

Presentation(s) S28 - Clinical Decision Making in MS (2:24 PM-2:32 PM)

Poster/Presentation
Number 003

Objective To assess factors associated with recovery from the coronavirus disease 2019 (COVID-19) among people with multiple sclerosis (pwMS)

Background It is important to understand the recovery process from COVID-19 among pwMS to identify those who are most vulnerable to the long-term sequelae of infection.

Design/Methods The UK MS Register COVID-19 study is a community-based prospective cohort of pwMS launched on March 17th, 2020. We have been collecting data from participants (n=6,618 as of October 5th, 2020) every two weeks from the time of their enrolment in the study. We ask participants about COVID-19 and follow them through their recovery. The UK MS Register holds pre-COVID-19 longitudinal and prospectively collected patient-reported data including web-based Expanded Disability Status Scale (webEDSS), MS Impact Scale (MSIS-29), and Hospital Anxiety and Depression Scale (HADS) scores.

Results Out of 709 participants with self-diagnosed COVID-19, 391 responded to the follow-up questionnaires. 76% (n=297) had fully recovered, 15.9% (n=62) had mostly recovered, and 8.2% (n=32) were still experiencing symptoms at the time of their latest follow-up. Among participants with full recovery, the median (IQR) duration of disease was 10 (6–21) days. Participants who had not recovered completely had been followed up for a median (IQR) duration of 105 (35–131) days. PwMS who had a higher webEDSS score (OR 0.78, 95%CI 0.65–0.93) or physical component of MSIS-29 score (OR 0.97, 95%CI 0.96–0.98) were less likely to report a full recovery. The presence of anxiety (HADS-anxiety ≥11), recorded the year before the pandemic, was associated with a lower probability of complete recovery (OR 0.26, 95%CI 0.10–0.66). Demographics, disease-modifying therapies, MS duration, or type of MS were not associated with recovery.

Conclusions Physical disability and anxiety prior to the pandemic are the main determinants of persistent COVID-19 symptoms among people with MS.

Authors/Disclosures
Afagh Garjani, MD (Nottingham University Hospitals NHS Trust) PRESENTER	The institution of Dr. Garjani has received research support from UK MS Society. Dr. Garjani has received personal compensation in the range of $0-$499 for serving as a Speaker with MS Academy. Dr. Garjani has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Biogen.
Richard S. Nicholas, FRCP (Imperial College Healthcare Trust)	Dr. Nicholas has nothing to disclose.
Rod Middleton (Data Scienve Building)	The institution of Mr. Middleton has received research support from MS Society.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Nikolaos Evangelou, PhD (Nottingham University, QMC campus)	Dr. Evangelou has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Evangelou has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for UK crown prosecution service. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis .

��ɫ��

��ɫ��